Loading clinical trials...

Persistent Pulmonary Hypertension of the Newborn | Clinical Trials | Clareo Health

TERMINATEDPHASE3

Persistent Pulmonary Hypertension of the Newborn

Multicenter, Double-blind, Placebo-controlled, Randomized, Prospective Study of Bosentan as Adjunctive Therapy to Inhaled Nitric Oxide in the Management of Persistent Pulmonary Hypertension of the Newborn (PPHN)

NCT01389856•Actelion

View on ClinicalTrials.gov

Summary

The AC-052-391-study is a phase 3 study to investigate whether adding bosentan to inhaled nitric oxide in newborns with persistent pulmonary hypertension of newborns (PPHN) is a supporting and safe therapy and to evaluate the pharmacokinetics of bosentan and its metabolites.

Eligibility

Age

0 - 0 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Signed informed consent by the parent(s) or the legal representative(s).
•2. Term and near term newborns (gestational age \> 34 weeks).
•3. Post natal age ≥ 12 hours and \< 7 days.
•4. Weight at birth ≥ 2,000 g.
•5. Idiopathic PPHN or PPHN due to parenchymal lung disease
•6. Documented diagnosis of pulmonary hypertension (PH) confirmed by echocardiography.
•7. Need for continued inhaled nitric oxide (iNO) at a dose \> 10ppm after at least 4 hours of continuous iNO treatment.
•8. Two oxygenation index (OI) values ≥ 12 taken at least 30 minutes apart, in the 12 hours prior to randomization and while the patient is receiving iNO treatment.
•9. Mechanical ventilation with fraction of inspired oxygen (FiO2) ≥ 50% at randomization.

Exclusion Criteria

•1. PH associated with conditions other than PPHN.
•2. Immediate need for cardiac resuscitation or extracorporeal membrane oxygenation (ECMO).
•3. Lethal congenital anomalies.
•4. Congenital Diaphragmatic Hernia.
•5. Significant structural cardiac anomalies.
•6. Medically significant pneumothorax.
•7. Active seizures.
•8. Expected duration of mechanical ventilation of less than 48 hours.
•9. Mean systemic blood pressure \< 35 mmHg despite therapy with volume infusions and cardiotonic support.
•10. Hepatic failure or all conditions with alanine aminotransferase (ALT) values \> 2 x upper limit of normal (ULN).
+7 more criteria

Key Dates

Start Date

December 1, 2011

Primary Completion Date

December 1, 2013

Completion Date

January 1, 2014

Last Updated

February 4, 2025

Enrollment

ACTUAL participants

Conditions

Persistent Pulmonary Hypertension of the Newborn

Interventions

Bosentan

DRUG

Matching placebo

DRUG